Central Nervous System Lymphoma: Novel Therapies

Area of Science:

• Neuro-oncology
• Hematology
• Clinical Therapeutics

Background:

• Primary central nervous system lymphomas (PCNSL) are rare and difficult to treat neoplasms.
• High-dose methotrexate (HD-MTX)-based regimens are the current standard first-line therapy.
• Optimal induction and consolidation therapies for PCNSL remain under investigation.

Purpose of the Study:

• To review recent advances in PCNSL treatment.
• To highlight the potential of targeted and immune therapies.
• To emphasize the importance of molecular profiling and clinical trials.

Main Methods:

• Review of current literature and clinical trial data.
• Analysis of emerging treatment strategies including targeted and immune therapies.
• Discussion of challenges and future directions in PCNSL research.

Main Results:

• Targeted and immune therapies demonstrate activity in relapsed/refractory PCNSL, often yielding durable responses.
• Molecular profiling may predict treatment response and elucidate relapse patterns.
• Advances in consolidation therapies include stem cell rescue and modified radiotherapy.

Conclusions:

• Targeted and immune therapies represent promising strategies for PCNSL treatment.
• Molecular profiling and collaborative clinical trials are crucial for advancing PCNSL care.
• Inclusive demographic consideration in future treatment algorithms is essential for equitable impact.